PL2376121T3 - Leczenie zapalenia kości i stawów - Google Patents

Leczenie zapalenia kości i stawów

Info

Publication number
PL2376121T3
PL2376121T3 PL09833924.5T PL09833924T PL2376121T3 PL 2376121 T3 PL2376121 T3 PL 2376121T3 PL 09833924 T PL09833924 T PL 09833924T PL 2376121 T3 PL2376121 T3 PL 2376121T3
Authority
PL
Poland
Prior art keywords
osteoarthritis treatment
osteoarthritis
treatment
Prior art date
Application number
PL09833924.5T
Other languages
English (en)
Other versions
PL2376121T5 (pl
Inventor
John Allan Hamilton
Andrew David Cook
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2376121(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2376121T3 publication Critical patent/PL2376121T3/pl
Publication of PL2376121T5 publication Critical patent/PL2376121T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
PL09833924T 2008-12-22 2009-12-21 Leczenie zapalenia kości i stawów PL2376121T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment
EP09833924.5A EP2376121B2 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (2)

Publication Number Publication Date
PL2376121T3 true PL2376121T3 (pl) 2016-12-30
PL2376121T5 PL2376121T5 (pl) 2021-09-27

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09833924T PL2376121T5 (pl) 2008-12-22 2009-12-21 Leczenie zapalenia kości i stawów

Country Status (19)

Country Link
US (4) US9243061B2 (pl)
EP (2) EP3056217B1 (pl)
JP (3) JP5727379B2 (pl)
KR (2) KR101799264B1 (pl)
CN (2) CN102271705A (pl)
AU (1) AU2009329814B2 (pl)
BR (1) BRPI0918356B1 (pl)
CA (1) CA2746827C (pl)
CY (1) CY1117698T1 (pl)
DK (1) DK2376121T4 (pl)
ES (2) ES2886063T3 (pl)
HK (1) HK1226938A1 (pl)
HR (1) HRP20160577T4 (pl)
HU (1) HUE028615T2 (pl)
PL (1) PL2376121T5 (pl)
RU (2) RU2712273C2 (pl)
SI (2) SI2376121T1 (pl)
SM (1) SMT201600156B (pl)
WO (1) WO2010071924A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2376121T1 (sl) 2008-12-22 2016-07-29 The University Of Melbourne Zdravljenje osteoartritisa
ES2685895T3 (es) 2008-12-22 2018-10-15 The University Of Melbourne Tratamiento del dolor
JP2015533806A (ja) 2012-09-20 2015-11-26 モルフォシス・アー・ゲー 関節リウマチの治療
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods for treating degenerative joint disease with cannabidiol gel through the skin
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH04503815A (ja) 1989-07-14 1992-07-09 シェリング・コーポレーション カルボキシル末端から誘導されたｇｍ―ｃｓｆのアンタゴニスト
EP0486572B1 (en) 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
AU5611394A (en) 1992-11-19 1994-06-08 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US20060067938A1 (en) * 2001-10-26 2006-03-30 Sherif Daouti Methods for the treatment of osteoarthritis and compositions thereof
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
ES2341461T5 (es) † 2004-02-11 2014-10-29 Warner-Lambert Company Llc Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
US7662573B2 (en) 2004-08-18 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Methods for evaluating osteoarthritis risk
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
CN103342751B (zh) 2005-04-18 2015-12-23 安进研发（慕尼黑）股份有限公司 人粒细胞巨噬细胞集落刺激因子的抗体中和剂
HUE058876T2 (hu) † 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR20080077237A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
PT1981909T (pt) * 2006-02-08 2017-01-18 Morphotek Inc Péptidos antigénicos do gm-csf e anticorpos contra o gm-csf
PT2423230E (pt) * 2006-03-27 2013-08-26 Medimmune Ltd Membro de ligação para o recetor de gm-csf
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
SG176503A1 (en) * 2006-11-21 2011-12-29 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US7879856B2 (en) * 2006-12-22 2011-02-01 Rigel Pharmaceuticals, Inc. Diaminothiazoles useful as Axl inhibitors
US20110044996A1 (en) * 2007-05-23 2011-02-24 Charles Mackay Neutralizing antibodies
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
WO2009062238A1 (en) 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
PT2215119E (pt) 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
US20100040630A1 (en) † 2008-03-24 2010-02-18 Aake Elden Methods and compositions for treating bone loss
AU2009243184B2 (en) 2008-04-28 2015-06-04 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
ES2685895T3 (es) † 2008-12-22 2018-10-15 The University Of Melbourne Tratamiento del dolor
SI2376121T1 (sl) 2008-12-22 2016-07-29 The University Of Melbourne Zdravljenje osteoartritisa
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体

Also Published As

Publication number Publication date
ES2886063T3 (es) 2021-12-16
JP2017200933A (ja) 2017-11-09
EP2376121B1 (en) 2016-03-09
EP2376121B2 (en) 2021-06-09
RU2011127334A (ru) 2013-01-27
ES2572368T3 (es) 2016-05-31
KR20170128630A (ko) 2017-11-22
BRPI0918356B1 (pt) 2022-03-08
HRP20160577T4 (hr) 2021-08-20
US20160185868A1 (en) 2016-06-30
RU2016102339A3 (pl) 2019-07-29
SI2376121T1 (sl) 2016-07-29
US20200247895A1 (en) 2020-08-06
AU2009329814A1 (en) 2010-07-01
RU2016102339A (ru) 2018-11-21
EP3056217B1 (en) 2021-06-30
JP2015143233A (ja) 2015-08-06
CN102271705A (zh) 2011-12-07
PL2376121T5 (pl) 2021-09-27
CA2746827A1 (en) 2010-07-01
SMT201600156B (it) 2016-08-31
BRPI0918356A2 (pt) 2020-10-06
US20120003234A1 (en) 2012-01-05
WO2010071924A1 (en) 2010-07-01
EP3056217A1 (en) 2016-08-17
JP2012512815A (ja) 2012-06-07
KR101799264B1 (ko) 2017-11-20
HK1226938A1 (zh) 2017-10-13
US20180066062A1 (en) 2018-03-08
DK2376121T3 (en) 2016-05-30
JP6458086B2 (ja) 2019-01-23
DK2376121T4 (da) 2021-08-16
HRP20160577T1 (hr) 2016-07-29
EP2376121A1 (en) 2011-10-19
SI2376121T2 (sl) 2021-11-30
AU2009329814B2 (en) 2015-06-18
JP5727379B2 (ja) 2015-06-03
ES2572368T5 (es) 2021-12-16
US9243061B2 (en) 2016-01-26
CY1117698T1 (el) 2017-05-17
CN106397591A (zh) 2017-02-15
KR101898982B1 (ko) 2018-09-14
EP2376121A4 (en) 2013-04-03
HUE028615T2 (en) 2016-12-28
KR20110128273A (ko) 2011-11-29
RU2712273C2 (ru) 2020-01-28
CA2746827C (en) 2018-01-23

Similar Documents

Publication Publication Date Title
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
EP2322076A4 (en) ENDOSCOPE OF TREATMENT
IL212348A0 (en) Treatment method
GB0822011D0 (en) Treatment
HK1226938A1 (zh) 骨關節炎治療
GB0711342D0 (en) Well treatment
GB0817067D0 (en) Intestinal treatment
GB0807850D0 (en) Treatment device
GB0811992D0 (en) Treatment
GB0900599D0 (en) Treatment
GB201013898D0 (en) Well treatment
GB0716784D0 (en) Well treatment
GB0802201D0 (en) Treatment system
GB0820972D0 (en) Treatment
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
PL2263454T3 (pl) Kompozycja uzdatniająca
GB0805912D0 (en) Treatment
GB0809046D0 (en) Cancer treatment
GB0823273D0 (en) Treatment system
GB2465211B (en) Treatment Solution
GB0820534D0 (en) Treatment
GB0821093D0 (en) Treatment
GB0816892D0 (en) Treatment